Figure 1 | Scientific Reports

Figure 1

From: Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure

Figure 1

Serological detection of M30-antigen (A), M65-antigen (B) and HMGB1 (C) in healthy controls, CHB and HBV-ACLF patients.

Results were presented as box plots including medians and 25th and 75th percentiles. The Kruskall-Wallis test was used for comparisons among multi-groups followed by Mann-Whitney U test for comparisons between two groups. In all three assays, cell death biomarkers were significantly elevated in HBV-ACLF patients compared with healthy controls (P < 0.001) and CHB patients (P< 0.001). In contrast to M30-antigen and M65-antigen, which discriminated (P< 0.001) CHB patients from healthy controls, no significant difference was found between the levels of HMGB1 (P= 0.601) in the two groups.

Back to article page